Back


20/09/2018
Asarina Pharma IPO oversubscribed 175%: CEO welcomes new shareholders
With its IPO listing oversubscribed by 175%, Asarina Pharma is firmly in the investor and scientific spotlight. Here, CEO Peter Nordkild shares upcoming research and business highlights with the company’s new shareholders. [...]

Download the pdf file





X

X